Chemwerth Chemwerth

X

Find Radio Compass News for Azacitidine

PharmaCompass
Related ProductsRelated Products
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES

0

https://www.globenewswire.com/news-release/2024/03/22/2851134/0/en/Salarius-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
22 Mar 2024

https://www.globenewswire.com//news-release/2024/01/03/2803302/0/en/Investigator-initiated-Phase-1-2-Clinical-Trial-Using-Salarius-Pharmaceuticals-Seclidemstat-in-Combination-with-Azacitidine-to-Treat-Hematologic-Cancers-Resumes-Patient-Enrollment.html

GLOBENEWSWIRE
03 Jan 2024

https://www.prnewswire.com/news-releases/akeso-published-results-from-cd47-antibody-ligufalimab-in-combination-with-azacitidine-for-newly-diagnosed-higher-risk-myelodysplastic-syndrome-and-treatment-naive-acute-myeloid-leukemia-at-ash-2023-302016538.html

PR NEWSWIRE
15 Dec 2023

https://www.globenewswire.com//news-release/2023/12/13/2795366/0/en/Shattuck-Labs-Announces-Positive-Initial-Topline-Data-from-Ongoing-Phase-1-A-B-Dose-Expansion-Clinical-Trial-of-SL-172154-with-Azacitidine-in-Frontline-Higher-Risk-Myelodysplastic-.html

GLOBENEWSWIRE
13 Dec 2023

https://www.businesswire.com/news/home/20231210537316/en

BUSINESSWIRE
10 Dec 2023

https://www.businesswire.com/news/home/20231206147296/en

BUSINESSWIRE
06 Dec 2023

https://www.prnewswire.com/news-releases/akeso-announced-fda-clearance-of-ind-for-cd47-monoclonal-antibody-ak117-in--combination-with-azacitidine-in-myelodysplastic-syndromes-301941140.html

PR NEWSWIRE
27 Sep 2023

https://www.gilead.com/news-and-press/press-room/press-releases/2023/7/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds

PRESS RELEASE
22 Jul 2023

https://www.accessdata.fda.gov/cms_ia/importalert_189.html

FDA
06 Jun 2023

https://www.businesswire.com/news/home/20230427006072/en

BUSINESSWIRE
15 May 2023

https://www.fiercebiotech.com/biotech/fda-puts-curis-leukemia-trial-partial-hold-after-patient-death-spurs-review-muscle

Nick Paul Taylor FIERCE BIOTECH
04 Apr 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215066

FDA
30 Dec 2022

https://www.globenewswire.com//news-release/2022/12/12/2572191/0/en/ORYZON-Presents-Final-Data-From-Phase-IIa-ALICE-Trial-in-Unfit-AML-Patients-with-First-line-Treatment-of-Iadademstat-and-Azacitidine-in-Oral-Presentation-at-ASH-2022.html

GLOBENEWSWIRE
12 Dec 2022

https://www.globenewswire.com//news-release/2022/12/12/2572030/0/en/ALX-Oncology-Announces-Initial-Data-from-ASPEN-05-Study-of-Evorpacept-in-Combination-with-Azacitidine-and-Venetoclax-Demonstrating-Tolerability-and-Preliminary-Activity-in-Patients.html

GLOBENEWSWIRE
12 Dec 2022

https://www.accesswire.com/731275/100-Clinical-Benefit-Rate-Achieved-in-Phase-1b-Trial-Evaluating-APVO436-in-Combination-with-Venetoclax-and-Azacitidine-for-Venetoclax-Treatment-Nave-Patients-with-Acute-Myeloid-Leukemia-AML

ACCESSWIRE
12 Dec 2022

https://www.businesswire.com/news/home/20221210005003/en

BUSINESSWIRE
10 Dec 2022

https://www.prnewswire.com/news-releases/innovent-presents-phase-1b-clinical-data-of-ibi188-anti-cd47-monoclonal-antibody-at-the-2022-american-society-of-hematology-annual-meeting-301699052.html

PRNEWSWIRE
10 Dec 2022

https://www.businesswire.com/news/home/20220915005108/en

BUSINESSWIRE
15 Sep 2022

https://apnews.com/article/health-cancer-clinical-trials-8a62525c9b47e96447f4f108dfd42791

APNEWS
15 Sep 2022

https://www.prnewswire.com/news-releases/i-mab-announces-approval-from-china-cde-to-initiate-phase-3-registrational-study-of-lemzoparlimab-in-combination-with-azacitidine-in-higher-risk-myelodysplastic-syndrome-301622810.html

PRNEWSWIRE
13 Sep 2022

https://www.prnewswire.com/news-releases/i-mab-announces-positive-phase-2-data-of-lemzoparlimab-in-combination-with-azacitidine-aza-in-patients-with-higher-risk-myelodysplastic-syndrome-at-esmo-2022-301621532.html

PRNEWSWIRE
11 Sep 2022

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-24-2022-1661335123.pdf

FDA
24 Aug 2022

https://endpts.com/abbvie-calls-off-phi-trial-for-i-mabs-cd47-days-after-zai-lab-shelves-its-own-program/

Kyle LaHucik ENDPTS
17 Aug 2022

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-august-17-2022-1660735823.pdf

FDA
17 Aug 2022

https://www.businesswire.com/news/home/20220803005673/en

BUSINESSWIRE
03 Aug 2022

https://www.globenewswire.com/news-release/2022/06/10/2460446/0/en/ORYZON-at-EHA-2022-Iadademstat-42-month-ALICE-Data-Demonstrate-Robust-Efficacy-in-Combination-with-Azacitidine-in-AML.html

GLOBENEWSWIRE
10 Jun 2022

https://endpts.com/servier-expands-tibsovo-label-with-first-combination-ok-in-a-rare-form-of-aml/

N. DeFeudis ENDPTS
27 May 2022

https://www.asiaone.com/business/servier-announces-fda-approval-tibsovo-ivosidenib-tablets-combination-azacitidine-patients

ASIAONE
26 May 2022

https://endpts.com/bristol-myers-dusts-off-an-old-celgene-chemotherapy-for-use-in-children-with-a-rare-blood-cancer/

Nicole DeFeudis ENDPTS
23 May 2022

https://www.prnewswire.com/news-releases/phase-3-agile-data-of-tibsovo-ivosidenib-tablets-in-combination-with-azacitidine-for-patients-with-previously-untreated-idh1-mutated-acute-myeloid-leukemia-published-in-the-new-england-journal-of-medicine-301529694.html

PRNEWSWIRE
21 Apr 2022

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-02-2022-1646291076.pdf

FDA
02 Mar 2022

https://www.businesswire.com/news/home/20220217005171/en

BUSINESSWIRE
17 Feb 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211549

FDA
03 Feb 2022

https://www.businesswire.com/news/home/20220202005820/en

BUSINESSWIRE
02 Feb 2022

https://endpts.com/in-a-setback-fda-orders-gilead-to-hit-the-brakes-on-their-late-stage-5b-cancer-play/

J. Carroll ENDPTS
26 Jan 2022

https://www.businesswire.com/news/home/20211216005141/en

BUSINESSWIRE
16 Dec 2021

https://www.fiercepharma.com/pharma/astellas-aml-drug-xospata-failed-its-trial-but-further-analysis-shows-it-benefited-some

K. Dunleavy FIERCEPHARMA
15 Dec 2021

https://www.businesswire.com/news/home/20211212005040/en

BUSINESSWIRE
12 Dec 2021

https://ir.alxoncology.com/news-releases/news-release-details/alx-oncology-announces-initial-data-aspen-02-ongoing-phase-1-2

PRESS RELEASE
12 Dec 2021

https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-azacitidine-1637387689.pdf

FDA
17 Nov 2021

https://www.businesswire.com/news/home/20211104005244/en

BUSINESSWIRE
04 Nov 2021

https://endpts.com/fda-orders-clinical-hold-on-apreas-p53-reactivator-as-struggling-biotech-pledges-to-address-safety-concerns/

Amber Tong ENDPTS
07 Aug 2021